Kinetics of cell migration to the dermis and hypodermis in dogs vaccinated with antigenic compounds of Leishmania braziliensis plus saponin

Vaccine

Volumn 26, Issue 31, 2008, Pages 3922-3931

  Vitoriano Souza, Juliana ^a   Reis, Alexandre B ^a,b   Moreira, Nádia D ^a   Giunchetti, Rodolfo C ^a,b   Correa Oliveira, Rodrigo ^b   Carneiro, Cláudia M ^a  

^a FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Canine visceral leishmaniasis; Inflammation and cell migration; Innate immune response; Saponin; Vaccine

Indexed keywords

ADJUVANT; ANTIGEN; INACTIVATED VACCINE; INDUCIBLE NITRIC OXIDE SYNTHASE; LEISHMANIA BRASILIENSIS PLUS SAPONIN VACCINE; LEISHMANIA VACCINE; SAPONIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL KINETICS; CELL MIGRATION; CONTROLLED STUDY; DERMIS; DOG; EDEMA; FEMALE; HISTOPATHOLOGY; IMMUNOGENICITY; IMMUNOREACTIVITY; INFLAMMATION; INNATE IMMUNITY; LEISHMANIA BRAZILIENSIS; LYMPHOCYTE COUNT; MALE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS TISSUE; VISCERAL LEISHMANIASIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL MOVEMENT; DERMIS; DOG DISEASES; DOGS; EOSINOPHILS; FEMALE; IMMUNITY, NATURAL; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; LYMPHOCYTES; MALE; NEUTROPHILS; NITRIC OXIDE SYNTHASE TYPE II; SAPONINS; SUBCUTANEOUS TISSUE;

EID: 46149087034     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.04.084     Document Type: Article

References (61)

1. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 27 (2004) 305-318
2. Deane L.M., and Deane M.P. Leishmaniose visceral urbana (no cão e no homem) em Sobral, Ceará. Hospital 47 (1955) 75-87
3. Chamizo C., Moreno J., and Alvar J. Semi-quantitative analysis of cytokine expression in asymptomatic canine leishmaniasis. Vet Immunol Immunopathol 103 (2005) 67-75
4. Reis A.B., Martins-Filho O.A., Teixeira-Carvalho A., Carvalho M.G., Mayrink W., Franca-Silva J.C., et al. Parasite density and impaired biochemical/hematological status are associated with severe clinical aspects of canine visceral leishmaniasis. Res Vet Sci 81 (2006) 68-75
5. Reis A.B., Teixeira-Carvalho A., Vale A.M., Marques M.J., Giunchetti R.C., Mayrink W., et al. Isotype patterns of immunoglobulins: hall-marks for clinical status and tissue parasite density in Brazilian dogs naturally infected by Leishmania (Leishmania) chagasi. Vet Immunol Immunopathol 112 (2006) 102-116
6. Reis A.B., Teixeira-Carvalho A., Giunchetti R.C., Guerra L.L., Carvalho M.G., Mayrink W., et al. Phenotypic features of circulating leucocytes as immunological markers for clinical status and bone marrow parasite density in dogs naturally infected by Leishmania chagasi. Clin Exp Immunol 146 (2006) 303-311
7. Giunchetti R.C., Mayrink W., Genaro O., Carneiro C.M., Correia-Oliveira R., Martins-Filho A.O., et al. Relationship between canine visceral leishmaniosis and the Leishmania (Leishmania) chagasi burden in dermal inflammatory foci. J Comp Pathol 135 (2006) 100-107
8. Lage R.S., Oliveira G.C., Busek S.U., Guerra L.L., Giunchetti R.C., and Correa-Oliveira R. Analysis of the cytokine profile in spleen cells from dogs naturally infected by Leishmania chagasi. Vet Immunol Immunopathol 115 (2007) 135-145
9. Baneth G., and Shaw S.E. Chemotherapy of canine leishmaniosis. Vet Parasitol 106 (2002) 315-324
10. Noli C., and Auxilia S.T. Treatment of canine Old World visceral leishmaniasis: a systematic review. Vet Dermatol 16 (2005) 213-232
11. Hommel M., Jaffe C.L., Travi B., and Milon G. Experimental models for leishmaniasis and for testing anti-leishmanial vaccines. Ann Trop Med Parasitol 89 Suppl 1 (1995) 55-73
12. Gradoni L. An update on anti-leishmanial vaccine candidates and prospects for a canine Leishmania vaccine. Vet Parasitol 100 (2001) 87-103
13. Mauel J. Vaccination against Leishmania infections. Curr Drug Targets Immune Endocr Metabol Disord 2 (2002) 201-226
14. Da Silva V., Borja-Cabrera G.P., Correia Pontes N.N., de Souza E.P., Luz K.G., and Palatnik M. A phase III trial of efficacy of the FML-vaccine against canine Kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN). Vaccine 19 (2000) 1082-1092
15. Borja-Cabrera G.P., Cruz Mendes A., Paraguai de Souza E., Hashimoto Okada L.Y., de A Trivellato F.A., Kawasaki J.K., et al. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine 22 (2004) 2234-2243
16. Lemesre J.L., Holzmuller P., Cavaleyra M., Goncalves R.B., Hottin G., and Papierok G. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Vaccine 23 (2005) 2825-2840
17. Lemesre J.L., Holzmuller P., Goncalves R.B., Bourdoiseau G., Hugnet C., Cavaleyra M., et al. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial. Vaccine 25 (2007) 4223-4234
18. Mayrink W., Genaro O., Silva J.C.F., da Costa R.T., Tafuri W.L., Peixoto Toledo V.P.C., et al. Phases I and II open clinical trials of a vaccine against Leishmania chagasi infections in dogs. Mem Inst Oswaldo Cruz 91 (1996) 695-697
19. Lasri S., Sahibi H., Sadak A., Jaffe C.L., and Rhalem A. Immune responses in vaccinated dogs with autoclaved Leishmania major promastigotes. Vet Res 30 (1999) 441-449
20. Panaro M.A., Acquafredda A., Lisi S., Lofrumento D.D., Mitolo V., and Sisto M. Nitric oxide production by macrophages of dogs vaccinated with killed Leishmania infantum promastigotes. Comp Immunol Microbiol Infect Dis 24 (2001) 187-195
21. Giunchetti R.C., Correa-Oliveira R., Martins-Filho O., Teixeira-Carvalho A., Roatt B.M., Aguiar-Soares R.D.O., et al. Immunogenicity of a killed Leishmania vaccine with saponin adjuvant in dogs. Vaccine 25 (2007) 7674-7686
22. Giunchetti R.C., Corrêa-Oliveira R., Martins-Filho O.A., Teixeira-Carvalho A., Roatt B.M., Aguiar-Soares R.D.O., et al. A killed Leishmania vaccine with sand fly saliva extract and saponin adjuvant displays immunogenicity in dogs. Vaccine 26 (2008) 623-638
23. Giunchetti R.C., Reis A.B., Da Silveira-Lemos D., Martins-Filho O.A., Corrêa-Oliveira R., Bethony J., et al. Antigenicity of a whole parasite vaccine as promising candidate against canine leishmaniasis. Res Vet Sci 85 (2008) 106-112
24. Badaró R., Rocha H., Carvalho E.M., Queiroz A.C., and Jones T.C. Leishmania donovani: an opportunistic infection associated with progressive disease in three immunocompromised patients. Lancet 8482 (1986) 647-649
25. Altes J., Salas A., Riera M., Udina M., Galmes A., Balanzat J., et al. Visceral leishmaniasis: another HIV-associated opportunistic infection? Report of eight cases and review of literature. AIDS 5 (1991) 201-220
26. Gradoni L., Scalone A., and Gramicia M. HIV-Leishmania co-infections in Italy: serological data as an indication of the sequence of acquisition of two infections. Trans R Soc Trop Med Hyg 87 (1993) 94-96
27. World Heath Organization. Magnitude of the problem (2008). http://www.who.int/leishmaniasis/burden/magnitude/burden_magnitude/en/index.html available at http://www.who.int/leishmaniasis/burden/magnitude/burden_magnitude/en/index.html [last accessed March 1, 2008]
28. Genaro O., de Toledo V.P., Da Costa C.A., Hermeto M.V., Afonso L.C., and Mayrink W. Vaccine for prophylaxis and immunotherapy, Brazil. Clin Dermatol 14 (1996) 503-512
29. Palatnik de Sousa C.B., Previato J.O., Mendonça-Previato L., and Borojevic R. A new approach to phylogeny of Leishmania: species-specificity of glycoconjugate ligands for promastigote internalization into murine macrophages. Parasitol Res 76 (1990) 289-293
30. Palatnik de Sousa C.B., Moreno M.B., Paraguai de Souza E., and Borojevic R. The FML vaccine (fucose-mannose ligand) protects hamsters from experimental Kala-azar. Cienc Cult (J Braz Assoc Adv Sci) 46 (1994) 290-296
31. Palatnik de Sousa C.B., Paraguai de Souza E., Gomes E.M., and Borojevic R. Experimental murine Leishmania donovani infection immunoprotection by fucose mannose ligand (FML). Braz J Med Biol Res 27 (1994) 547-551
32. Borja-Cabrera G.P., Correia Pontes N.N., Da Silva V.O., Paraguai de Souza E., Santos W.R., Gomes E.M., et al. Long lasting protection against canine Kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonzalo do Amarante, RN). Vaccine 20 (2002) 3277-3284
33. Teixeira C.R., Teixeira M.J., Gomes R.B.B., Santos C.S., Andrade B.B., Raffaele-Neto I., et al. Saliva from Lutzomyia longipalpis induces CC chemokine ligand 2/monocyte chemoattractant protein-1 expression and macrophage recruitment. J Immunol 175 (2005) 8346-8353
34. Cohen S. Cell mediated immunity and the inflammatory system. Hum Pathol 7 (1976) 249-264
35. Dunn C.J., Hardee M.M., and Staite N.D. Acute and chronic inflammatory responses to local administration of recombinant IL-1 alpha, IL-beta, TNF alpha, IL-2 and IFN gamma in mice. Agents Actions 27 (1989) 290-293
36. Berg D.J., Leach M.W., Kühn R., Rajewsky K., Müller W., Davidson N.J., et al. Interleukin 10 but not interleukin 4 is a natural suppressant of cutaneous inflammatory responses. J Exp Med 182 (1995) 99-108
37. Stewart R.J., Holloway L.J., and Isbister W.H. Peritoneal neutrophilia: a potential indicator of the surgical acute abdomen. Aust NZ J Surg 54 (1984) 565-568
38. De Souza, RCA. Estudo da cinética celular da resposta inflamatória causada pela crioterapia experimental em pele normal de camundongos utilizando o método de bolsas de ar no subcutâneo. MSc dissertation. Florianópolis: Universidade Federal de Santa Catarina; 2001.
39. Jancar S. Imunidade natural e inflamação. In: Calish V., and Vaz C. (Eds). Imunologia (2001), Editora Revinter, Rio de Janeiro 11-29
40. Parra L.E., Borja-Cabrera G.P., Santos F.N., Souza L.O., Palatnik-de-Sousa C.B., and Menz I. Safety trial using the Leishmune vaccine against canine visceral leishmaniasis in Brazil. Vaccine 25 (2007) 2180-2186
41. Kensil C.R. Saponins as vaccine adjuvants. Crit Rev Ther Drug 13 (1996) 1-55
42. Houdayer M., Rouze P., Dalsgaard K., and Metzger J.J. Adjuvant effect of Quil A in porcine humoral immune response. Ann Immunol Cell Biol (Institute Pauster) 129 1 (1978) 107-112
43. De Oliveira C.A.C., Perez A.C., Merino G., Prieto J.G., and Alvarez A.I. Protective effects of Panax ginseng on muscle injury and inflammation after eccentric exercise. Comp Biochem 130 (2001) 369-377
44. Appelberg R. Neutrophils and intracellular pathogens: beyond phagocytosis and killing. Trends Microbiol 15 (2007) 87-92
45. Beauvillain C., Delneste Y., Scotet M., Peres A., Gascan H., Guermonprez P., et al. Neutrophils efficiently cross-prime naive T cells in vivo. Blood 110 (2007) 2965-2973
46. Scapini P., Lapinet-Vera J.A., Gasperini S., Calzetti F., Bazzoni F., and Cassatella M.A. The neutrophil as a cellular source of chemokines. Immunol Rev 177 (2000) 195-203
47. Terui T., Ozawa M., and Tagami H. Role of neutrophils in induction of acute inflammation in T-cell-mediated immune dermatosis, psoriasis: a neutrophil-associated inflammation-boosting loop. Exp Dermatol 9 (2000) 1-10
48. Berg R.E., and Forman J. The role of CD8 T cells in innate immune and in antigen non-specific protection. Curr Opin Immunol 18 (2006) 338-343
49. Bittar R.C., Nogueira R.S., Vieira-Gonçalves R., Pinho-Ribeiro V., Mattos M.S., Oliveira-Neto M.P., et al. T-cell responses associated with resistance to leishmania infection in individuals from endemic areas for Leishmania (Viannia) braziliensis. Mem Inst Oswaldo Cruz 102 (2007) 625-630
50. Nathan C., and Xie Q. Nitric oxide synthases: roles, tolls, and controls. Cell 78 (1994) 915-918
51. Nathan C., and Xie Q. Regulation of biosynthesis of nitric oxide. J Biol Chem 269 (1994) 13725-13728
52. Hall L.R., and Titus R.G. Sandfly vector saliva selectively modulates macrophage functions that inhibit killing of L. major and nitric oxide production. J Immunol 155 (1995) 3501-3506
53. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2 (2001) 907-916
54. Liew F.Y., Wei X.Q., and Proudfoot L. Cytokines and nitric oxide as effector molecules against parasitic infections. Philos Trans Roy Soc B 352 (1997) 1311-1315
55. Liew F.Y., and O'Donnell C.A. Immunology of leishmaniasis. Adv Parasitol 32 (1993) 161-259
56. Bogdan C., Vodovotz Y., Paik J., Xie Q.W., and Nathan C. Traces of bacterial lipopolysaccharide suppress IFN-gamma-induced nitric oxide synthase gene expression in primary mouse macrophages. J Immunol 151 (1993) 301-309
57. Vouldoukis I., Becherel P.A., Riveros-Moreno V., Arock M., Da Silva O., Debre P., et al. Interleukin-10 and interleukin-4 inhibit intracellular killing of Leishmania infantum and Leishmania major by human macrophages by decreasing nitric oxide generation. Eur J Immunol 27 (1997) 860-865
58. Ross R., and Reske-Kunz A.B. The role of NO in contact hypersensitivity. Int Immunopharmacol 1 (2001) 1469-1478
59. Kaim U., Moritz A., Failing K., and Baumgärtner W. The regression of a canine Langerhans cell tumour is associated with increased expression of IL-2, TNF-alpha, IFN-gamma and iNOS mRNA. Immunology 118 (2006) 472-482
60. Bonhoeffer J., Kohl K., Chen R., Duclos P., Heijbel H., Heininger U., et al. The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine 13 (2002) 298-302
61. Rothstein E., Kohl K.S., Ball L., Halperin S.A., Halsey N., Hammer S.J., et al. Nodule at injection site as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine 22 (2004) 575-585